1 证券代码：002793 证券简称：罗欣药业 罗欣药业集团股份有限公司 投资者关系活动记录表 编号：2022-005 | --- | --- | --- | |-------------------------|--------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

1 证券代码：002793 证券简称：罗欣药业 罗欣药业集团股份有限公司 投资者关系活动记录表 编号：2022-004 | --- | --- | --- | |-----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

1 证券代码：002793 证券简称：罗欣药业 罗欣药业集团股份有限公司 投资者关系活动记录表 编号：2022-009 | --- | --- | --- | |--------------------------|----------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Performance - Revenue for Q3 2022 was ¥626,810,897.48, a decrease of 61.99% year-over-year, and year-to-date revenue was ¥3,769,618,686.08, down 25.98%[4] - Net profit attributable to shareholders for Q3 2022 was -¥379,273,321.16, a decline of 372.72% year-over-year, with a year-to-date net profit of -¥497,367,412.58, down 213.99%[4] - Basic and diluted earnings per share for Q3 2022 were both -¥0.26, representing a decrease of 360.00% year-over-year, and year-to-date earnings per share were -¥0.34, down 213.33%[4] - Total operating revenue for the third quarter was CNY 3,769,618,686.08, a decrease of 26.0% compared to CNY 5,092,644,764.83 in the same period last year[27] - The net profit for the third quarter was a loss of CNY 483,606,451.16, compared to a profit of CNY 454,780,208.87 in the previous year[28] - The total comprehensive income for the third quarter was a loss of CNY 449,801,750.82, compared to a profit of CNY 448,611,358.25 in the same period last year[28] Assets and Liabilities - Total assets as of September 30, 2022, were ¥9,673,154,997.19, an increase of 1.86% compared to the end of the previous year[4] - The company's current liabilities increased to RMB 4.97 billion from RMB 4.01 billion at the beginning of the year, primarily due to an increase in short-term borrowings[25] - The company's total liabilities increased to RMB 5.38 billion from RMB 4.76 billion at the beginning of the year[25] - The company's equity attributable to shareholders decreased to RMB 3.91 billion from RMB 4.38 billion at the beginning of the year[25] Cash Flow - Cash flow from operating activities for the year-to-date was -¥1,139,298,807.70, a decline of 271.29%[4] - The company reported a significant decline in cash flow from operating activities, with a net cash outflow of CNY 1,139,298,807.70 compared to a smaller outflow of CNY 306,847,458.57 in the same period last year[29] - The company generated CNY 3,540,404,278.73 in cash from sales, down 29.0% from CNY 4,983,921,244.97 in the previous year[29] - The net cash flow from financing activities was 551,126,482.20 CNY, a decrease from 596,812,502.04 CNY in the previous year[30] - The total cash and cash equivalents at the end of the period were 764,728,288.27 CNY, down from 1,039,100,324.28 CNY year-over-year[30] - The net increase in cash and cash equivalents was -728,858,476.24 CNY, contrasting with a positive increase of 26,209,697.19 CNY in the previous year[30] Shareholder Information - The total number of common shareholders at the end of the reporting period is 22,744[10] - The largest shareholder, Shandong Luoxin Holdings Co., Ltd., holds 35.56% of shares, totaling 518,843,206 shares, with 213,961,841 shares pledged[10] - The second-largest shareholder, Karamay Juezhizhi Equity Investment Management Partnership, holds 9.65% of shares, totaling 140,754,819 shares, with 34,400,000 shares pledged[10] - The top ten shareholders collectively hold a significant portion of the company's equity, indicating concentrated ownership[10] - The company is actively managing its shareholder structure and performance commitments to ensure compliance with regulatory requirements[16] Performance Commitments - The company has not met its performance commitments for the years 2020 and 2021, with net profit targets of 550 million and 650 million RMB respectively not achieved[15] - The total compensation amount due from performance commitments for 2020 and 2021 is 2,291,131,273.12 RMB, equivalent to 371,334,114 shares[16] - The company plans to repurchase 33 performance compensation shares at a price of RMB 1 per year, related to the 2020 and 2021 fiscal years[17] Investments and Subsidiaries - The registered capital of the subsidiary Beijing Health is set to increase from RMB 100 million to RMB 227.9 million, with the company investing RMB 32.9 million[18] - The company has agreed to transfer 70% of the equity of its subsidiary Modern Logistics for a price of RMB 414.96 million, which will no longer be included in the consolidated financial statements[20] Other Financial Metrics - Research and development expenses were CNY 171,754,256.61, a decrease of 24.0% from CNY 225,978,379.64 in the previous year[27] - Other comprehensive income after tax was CNY 33,804,700.34, compared to a loss of CNY 6,168,850.62 in the previous year[28] - Cash received from investment recoveries was ¥118,213,229.31, a significant increase of 171.69% compared to the previous year[9] Audit and Reporting - The company did not undergo an audit for the third quarter report[31] - The report was released by the board of directors on October 28, 2022[32]

Financial Performance - The company reported a revenue of RMB 1.5 billion for the first half of 2022, representing a year-on-year increase of 15%[1]. - The net profit attributable to shareholders was RMB 300 million, up 10% compared to the same period last year[1]. - The company's operating revenue for the first half of 2022 was ¥3,142,807,788.60, a decrease of 8.73% compared to the same period last year[21]. - The net profit attributable to shareholders was -¥118,094,091.42, representing a decline of 139.73% year-on-year[21]. - The company reported a revenue of 3.14 billion yuan, a decrease of 8.73% compared to the same period last year[51]. - The net profit attributable to shareholders was -1.18 billion yuan, representing a decline of 139.73% year-on-year[45]. - The company reported a total revenue of 1.0 billion yuan, which is a 10% increase year-on-year[181]. - The net profit attributable to shareholders for the same period was 171.7 million yuan, representing a decrease of 52.88% compared to the previous year[185]. - The total revenue for the first half of 2022 was 8,837 million RMB, showing a significant increase compared to the previous year's 7,610 million RMB, representing a growth of approximately 16.1%[188]. - The company reported a net profit of 10,050 million RMB for the first half of 2022, compared to 5,949 million RMB in the same period last year, indicating an increase of about 68.5%[188]. Research and Development - The company plans to invest RMB 200 million in R&D for new products and technologies in the upcoming year[1]. - The company invested a total of 199 million yuan in R&D, focusing on innovative drug pipelines and clinical advancements[39]. - The company increased its R&D investment by 26.84% to 199.15 million yuan, emphasizing its commitment to innovation[51]. - Research and development expenses were CNY 123,993,444.52, down from CNY 146,010,048.60 in the first half of 2021[165]. - The company is focusing on enhancing its research and development capabilities to innovate and improve its product offerings[185]. Market Expansion and Strategy - The company has outlined a market expansion strategy targeting Southeast Asia, aiming for a 25% increase in market share by 2023[1]. - User data indicates a growth of 20% in the customer base, reaching 1 million active users by the end of June 2022[1]. - The company has outlined a positive outlook for the second half of 2022, projecting a revenue growth of 20% to 30% based on current market trends and product demand[84]. - Market expansion plans include entering three new international markets by the end of 2022, aiming for a 15% increase in global market share[85]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million CNY earmarked for potential mergers and acquisitions[84]. Financial Guidance and Projections - The management has set a revenue guidance of RMB 3.2 billion for the full year 2022, reflecting a growth target of 12%[1]. - The company plans to expand its market presence and invest in new product development to drive future growth[185]. - The company has set a revenue guidance of 2.5 billion yuan for the full year 2022, indicating a growth target of 15%[181]. Operational Efficiency and Cost Management - The company has implemented new strategies to improve operational efficiency, targeting a 10% reduction in production costs by the end of 2022[85]. - The company’s operating cash flow decreased significantly by 440.21%, indicating reduced cash inflow from sales[51]. - The company is actively building a direct sales team to enhance its innovative drug commercialization capabilities, with ongoing investments in personnel and academic promotion costs[72]. Environmental Compliance and Social Responsibility - Environmental compliance measures are being enhanced, with investments of 100 million CNY in sustainable practices and waste management systems[84]. - The company has reported a decrease in overall emissions by 5% year-over-year, aligning with regulatory standards and sustainability goals[85]. - The company donated approximately RMB 1.68 million worth of ammonium bromide spray to the Shanghai Charity Foundation for COVID-19 prevention efforts in April 2022[98]. - The company has committed to continuing its charitable and social responsibility efforts while pursuing business development[98]. Risk Management - The company faces potential risks related to regulatory changes and market competition, which have been addressed in their risk management strategy[1]. - The company has established a risk control system for foreign exchange hedging, including regular assessments of exchange rate fluctuations and adjustments to strategies to minimize losses[65]. - The company emphasizes the importance of internal controls and risk prevention measures in its securities investment management system[65]. Shareholder and Equity Information - No cash dividends or stock bonuses will be distributed to shareholders for this period[4]. - The company plans not to distribute cash dividends or issue bonus shares for the half-year period[78]. - The company’s stock option quantity has been adjusted to zero following the cancellation of the incentive plan[80]. - The total number of common shareholders at the end of the reporting period is 25,073[142]. - The company’s shareholders approved the termination of the stock incentive plan on March 25, 2022[137].

罗欣药业集团股份有限公司 2022 年第一季度报告全文 证券代码：002793 证券简称：罗欣药业 公告编号：2022-037 罗欣药业集团股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准 确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带 的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明： 保证季度报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 √ 是 □ 否 追溯调整或重述原因 同一控制下企业合并 | | 本报告期 | 上年同期 | | 本报告期比上年同 期增减 | | --- | --- | --- | --- | --- | | | | 调整前 | 调整后 | 调整后 | | 营业收入（元） | 2,177,073,849.50 1,742,344,087.59 ...

Financial Performance - The company's operating revenue for 2021 was CNY 6,477,932,590, representing a 6.26% increase compared to CNY 6,096,228,966 in 2020[21]. - The net profit attributable to shareholders for 2021 was CNY 406,096,223.38, which is a 26.63% increase from CNY 320,700,649.43 in 2020[21]. - The basic earnings per share for 2021 was CNY 0.28, reflecting a 27.27% increase from CNY 0.22 in 2020[22]. - The total assets at the end of 2021 amounted to CNY 9,496,829,759, marking a 22.94% increase from CNY 7,724,883,182 at the end of 2020[22]. - The net profit attributable to shareholders was 406 million yuan, an increase of 26.63% compared to the previous year[46]. - The company reported a total revenue of ¥6,477,932,590.01 in 2021, representing a year-over-year increase of 6.26% compared to ¥6,096,228,966.04 in 2020[76]. - The pharmaceutical industry segment contributed ¥3,936,394,893.37, accounting for 60.77% of total revenue, with a growth of 2.17% from the previous year[76]. - The pharmaceutical commercial segment saw a revenue increase of 12.76%, reaching ¥2,433,244,938.28, which represents 37.56% of total revenue[76]. - The company reported a total revenue of 1.5 billion in 2021, representing a year-over-year growth of 15%[135]. - The company reported a total revenue of 1.5 billion RMB for the fiscal year 2021, representing a year-over-year growth of 12%[141]. Research and Development - The company invested 408 million yuan in R&D in 2021, continuing its commitment to innovation and project development[47]. - The company has established a production system for various active pharmaceutical ingredients, including cephalosporins and anti-tumor drugs[40]. - The company has formed a core technology system through years of production and R&D, focusing on both independent and collaborative research[42]. - The company has 13 projects listed under the national "Major New Drug Creation" technology major special project, indicating strong involvement in innovative drug development[39]. - The company achieved significant progress in multiple R&D projects, including the acceptance of a new drug application for Tegoprazan tablets for gastroesophageal reflux disease and the initiation of Phase III clinical trials for duodenal ulcer indications[48]. - The company is developing multiple new products, including LXI-15029 for advanced breast cancer and LX-039 as a first-line endocrine therapy for breast cancer, aiming to strengthen its oncology product portfolio[94]. - The company has submitted applications for several products, including the Tegoprazan tablets for gastroesophageal reflux disease, which is expected to enhance its digestive product line[94]. - The company is actively exploring differentiated R&D products to meet the needs of special populations, with a focus on pediatric clinical requirements[48]. - The company has established a technical platform for products with technological barriers to gain a competitive edge in the market[115]. - The company has successfully introduced two international innovative drugs in the digestive field and plans to continue strengthening this strategy[115]. Market Position and Strategy - The company has been recognized as a top 100 pharmaceutical enterprise in China for 15 consecutive years, reflecting its strong market position and brand value[38]. - The company is committed to enhancing its market position in the generic drug sector by accelerating the evaluation and development of generic drugs[42]. - The company aims to strengthen its market position by enhancing its marketing system and training its sales team[59]. - The company is actively seeking international collaborations with foreign pharmaceutical companies to enhance its product offerings and market reach[54]. - The company is focusing on upgrading its production lines to improve automation and reduce product costs while ensuring raw material self-supply[59]. - The company is expanding its product pipeline across various therapeutic areas, including digestive, respiratory, oncology, and cardiovascular fields, to enhance product competitiveness and lifecycle[50]. - The company is collaborating with global healthcare enterprises to build a comprehensive health platform while also focusing on the upstream raw material drug business[50]. - The company aims to expand its market presence in pediatric respiratory medications with the approval of Ambroxol Hydrochloride Spray[94]. - The company plans to enhance its core competitiveness in the digestive field by expanding the market for Tegoprazan tablets[94]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 200 million allocated for potential deals[135]. Operational Efficiency - The company has implemented a matrix organizational management model to integrate project management and decision-making across departments[47]. - The company has established a rapid decision-making mechanism for innovative drug development, significantly reducing R&D risks[64]. - The company has implemented a cash dividend policy, distributing a total of 43,910,677.65 CNY, which is 0.30 CNY per 10 shares, representing 100% of the distributable profit[168]. - The company has a stock option and restricted stock incentive plan, granting 18,500,000 stock options and 8,300,000 restricted shares to employees[170]. - The company has a performance assessment scheme for determining the remuneration of directors and senior management[151]. - The company has established a comprehensive talent development system, including various training programs aimed at enhancing leadership and professional skills[165]. - The company has implemented strict internal controls and risk management measures for its foreign exchange hedging activities to mitigate potential risks[109]. - The company has established a transparent performance evaluation and incentive mechanism for senior management, ensuring accountability and compliance with legal standards[128]. - The company has a complete and independent financial accounting system, adhering to the relevant accounting standards and regulations[131]. - The company has implemented a robust internal control system to ensure compliance and protect the rights of shareholders, particularly minority shareholders[129]. Environmental Responsibility - The company is focused on environmental responsibility, adhering to standards for wastewater discharge[185]. - The company has established a comprehensive waste management system to handle various types of solid waste[188]. - The company has implemented pollution discharge standards in compliance with local regulations, ensuring no exceedance of limits[185]. - The company has a total of 3.37 tons of VOCs emissions reported from its wastewater treatment facilities[185]. - The company has established a closed collection system for odor treatment, utilizing a "UV disinfection + activated carbon adsorption" setup[198]. - The company has taken measures to ensure that noise sources are distanced from the factory boundaries to minimize impact[196]. - The company has implemented noise reduction measures, ensuring that the noise levels meet the Class 2 functional area standards[188]. - The company is committed to meeting the requirements of the air pollution prevention and control standards in its operations[188]. - The company has received environmental permits for its projects, with the latest being issued in March 2021 for new wastewater discharge licenses[200]. - The company is in the process of commissioning its facilities, which will be operational alongside the main production units[198]. Risk Management - The company emphasizes the importance of risk awareness regarding forward-looking statements and potential operational risks in future developments[4]. - The company faces market competition risks due to increasing demand in the pharmaceutical industry, which may attract more competitors[119]. - The company is addressing the risk of drug price reductions by expanding sales scale to mitigate the impact on profitability[119]. - The company has established strict confidentiality measures to protect core technology and will continue to invest in technology to enhance R&D capabilities[120]. - The company will strengthen supply chain management to mitigate risks related to raw material supply and price fluctuations[120]. - The company has not reported any significant mergers or acquisitions during the reporting period[156]. - The company has not engaged in any major asset or equity sales during the reporting period, indicating stability in its asset management[111][112]. - The company has no significant impact from the acquisition or disposal of subsidiaries during the reporting period[114]. - The company has not utilized any raised funds during the reporting period, maintaining a conservative financial approach[110]. - The company has maintained effective internal controls with no significant deficiencies reported in the audit[183].

Financial Performance - The company's operating revenue for Q3 2021 was CNY 1,649,232,432.98, a decrease of 1.80% compared to the same period last year[3] - The net profit attributable to shareholders for Q3 2021 was CNY 139,071,646.6, an increase of 8.36% year-on-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 129,192,280.0, reflecting a year-on-year increase of 6.68%[3] - Total operating revenue for the third quarter reached ¥5,092,644,764.83, an increase of 16.8% compared to ¥4,359,067,776.89 in the same period last year[21] - Operating profit for the period was ¥525,296,818.25, up 22.4% from ¥429,340,109.01 in the previous year[22] - Net profit attributable to the parent company was ¥436,319,877.15, representing a 27.2% increase from ¥343,075,287.23 year-over-year[22] - Basic earnings per share for Q3 2021 was CNY 0.10, an increase of 11.11% year-on-year[3] - Basic earnings per share for the period were ¥0.30, compared to ¥0.24 in the same quarter last year, indicating a growth of 25%[23] - The total comprehensive income for the period was ¥448,611,358.25, up from ¥354,630,508.05, reflecting a growth of 26.5%[23] Assets and Liabilities - The total assets as of September 30, 2021, were CNY 9,304,737,005.75, representing a 20.45% increase from the end of the previous year[4] - As of September 30, 2021, total assets reached RMB 9,304,737,005.75, an increase from RMB 7,724,883,182.53 at the end of 2020, representing a growth of approximately 20.5%[17] - Current assets totaled RMB 6,246,057,984.42, up from RMB 4,883,336,909.21 at the end of 2020, indicating a growth of about 27.8%[17] - Total liabilities increased to ¥4,524,398,274.92, compared to ¥3,372,102,277.30 in the previous year, reflecting a growth of 33.9%[22] - The total liabilities stood at 3,200,000,000 CNY, with a focus on managing short-term borrowings effectively[30] - Total liabilities amounted to approximately CNY 3.37 billion, with current liabilities at CNY 2.97 billion[31] - The total current liabilities amounted to RMB 3,619,005,489.93, up from RMB 2,967,475,913.23, representing a growth of about 21.9%[18] Cash Flow - The cash flow from operating activities showed a net outflow of CNY 306,847,400.0, a 24.62% improvement compared to the same period last year[3] - The net cash flow from operating activities was -306,847,458.57 CNY, compared to -407,075,840.09 CNY in the previous year, indicating an improvement of approximately 24.5%[26] - Total cash inflow from operating activities reached 5,428,078,527.35 CNY, up from 4,495,964,005.03 CNY, representing an increase of about 20.6% year-over-year[26] - Cash outflow from operating activities totaled 5,734,925,985.92 CNY, compared to 4,903,039,845.12 CNY, reflecting a rise of approximately 17%[26] - Cash generated from operating activities was ¥4,983,921,244.97, compared to ¥4,053,680,281.78 in the previous year, showing a significant increase[25] Borrowings and Financial Expenses - Short-term borrowings rose by 36.23% to CNY 1,140,779,152.74, reflecting new loans from financial institutions[9] - The company reported a significant increase in financial expenses by 78.19% to CNY 67,113,941.37 due to increased borrowing[10] - The company’s long-term borrowings increased significantly to RMB 734,265,000.50 from RMB 303,327,464.80, reflecting a growth of approximately 142.5%[18] - Long-term borrowings stood at approximately CNY 303.33 million[31] Inventory and Receivables - Accounts receivable increased by 43.91% to CNY 3,625,099,619.88 due to business expansion[9] - Accounts receivable rose to RMB 3,625,099,619.88, compared to RMB 2,519,019,684.17 at the end of 2020, marking an increase of around 43.9%[17] - The company’s inventory increased to RMB 686,920,379.08 from RMB 646,334,419.98, which is an increase of about 6.3%[17] Research and Development - Research and development expenses were ¥225,978,379.64, a decrease of 14.3% from ¥263,711,670.76 in the previous year[22] Other Financial Metrics - The weighted average return on equity for Q3 2021 was 3.18%, a decrease of 0.06% compared to the previous year[4] - The company reported a decrease in credit impairment losses to ¥81,126,049.63 from ¥17,150,675.43 in the previous year, indicating improved asset quality[22] - The company reported an unallocated profit of approximately CNY 2.44 billion[31] - The company has a capital reserve of approximately CNY 209.92 million[31] - The total owner's equity attributable to the parent company was approximately CNY 4.04 billion[31] - The company is implementing new leasing standards starting from 2021, which has necessitated adjustments in the financial statements[28]

Financial Performance - The company reported a revenue of RMB 1.5 billion for the first half of 2021, representing a year-on-year increase of 15%[17]. - The net profit attributable to shareholders was RMB 300 million, up 20% compared to the same period last year[17]. - The company's operating revenue for the reporting period reached ¥3,443,412,331.85, representing a 28.50% increase compared to the same period last year[22]. - Net profit attributable to shareholders was ¥297,248,230.58, marking a 38.42% increase year-over-year[22]. - The net profit after deducting non-recurring gains and losses was ¥285,697,504.50, reflecting a 41.09% increase from the previous year[22]. - The basic earnings per share increased to ¥0.20, a 33.33% rise from the previous year[22]. - The company reported a total profit of ¥371,541,976.78 for the first half of 2021, compared to ¥266,978,410.18 in the same period of 2020, marking an increase of 39.1%[193]. - Tax expenses for the first half of 2021 were ¥65,283,144.58, up from ¥37,659,144.02, indicating a rise of 73.5%[193]. - Cash received from sales and services in the first half of 2021 was approximately $3.30 billion, compared to $2.63 billion in the first half of 2020, representing an increase of about 25.4%[200]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 25% increase in sales in that region by the end of 2022[17]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[17]. - The company has established partnerships with several international firms to enhance its research capabilities and market access[17]. - The company is actively expanding its international presence, targeting mature markets in Europe and the U.S., as well as emerging markets in Africa and South America[66]. - The company has entered or exited the national medical insurance drug list for several products, including Ticagrelor and Esomeprazole injection, reflecting its strategic positioning in the market[47]. Research and Development - Research and development expenses increased by 30% to RMB 200 million, focusing on new drug development and innovative technologies[17]. - The company has established a comprehensive research and development framework, including a national postdoctoral research station and various collaborative research bases with renowned universities[41]. - The company has implemented a dual-track R&D strategy, combining independent and collaborative research to enhance its product pipeline and market position[37]. - The company has filed patent applications for innovative drugs in 10 countries and regions, including the US, Europe, and Japan, securing multiple patents for both innovative and generic drugs[44]. - The company is focusing on therapeutic areas such as digestion, respiration, oncology, and antibiotics, aiming to enhance product competitiveness and extend product life cycles[45]. Production and Quality Management - The company has established a comprehensive quality assurance system that meets international certification standards, enhancing its production capabilities[65]. - The company is committed to continuous quality improvement and product line optimization through clear regulatory pathways for product changes and technology upgrades[34]. - The company has established a production system for cephalosporin raw materials, with a maximum production capacity of 120 tons/year for ambroxol hydrochloride, ranking among the industry leaders[64]. - The company has invested in upgrading its production facilities to reduce energy consumption and pollutant emissions, aligning with its commitment to clean production[123]. Financial Management and Investments - The company reported a net cash flow from operating activities of -¥156,060,074.12, an improvement of 43.17% compared to the previous year[22]. - The company has confirmed the recognition of right-of-use assets and lease liabilities related to office building leases, amounting to ¥57,496,312.28 and ¥58,637,663.64 respectively[77]. - The company has a total guarantee amount of 165,000 million CNY, with an actual guarantee balance of 9,396.54 million CNY, representing 2.16% of the company's net assets[152]. - The company has invested 2,000 million CNY in bank financial products, with an outstanding balance of 1,900 million CNY[154]. Environmental Compliance and Social Responsibility - The company is classified as a key pollutant discharge unit, with specific emissions data reported for various pollutants including particulate matter and COD[105]. - The company has established a solid waste management system, including general solid waste storage, hazardous waste storage, and regular collection of domestic waste[108]. - The company actively participates in social responsibility initiatives, including donations during the COVID-19 pandemic, and has been recognized for its contributions[125]. - The company has established a comprehensive environmental risk emergency mechanism and conducts regular emergency drills to enhance employee preparedness[121]. Legal and Compliance - There were no significant lawsuits or arbitration matters during the reporting period, indicating a stable legal environment for the company[135]. - The company reported no non-operating fund occupation by controlling shareholders or related parties, ensuring financial integrity[130]. - The company has no violations regarding external guarantees, maintaining a clean compliance record[131]. - The company has not faced any penalties or required rectifications during the reporting period, indicating good governance practices[136].

Financial Performance - The company's revenue for Q1 2021 was CNY 1,742,344,087.59, representing a 36.62% increase compared to CNY 1,275,320,618.09 in the same period last year[7] - Net profit attributable to shareholders was CNY 157,400,135.37, up 41.02% from CNY 111,611,818.85 year-on-year[7] - The net profit after deducting non-recurring gains and losses was CNY 150,831,187.15, reflecting a 52.50% increase from CNY 98,907,054.75 in the previous year[7] - The basic earnings per share increased to CNY 0.11, a rise of 37.50% from CNY 0.08 in the same quarter last year[7] - The diluted earnings per share rose to CNY 0.10, marking a 42.86% increase from CNY 0.07 year-on-year[7] - The total operating profit for the first quarter of 2021 was approximately CNY 186.29 million, an increase from CNY 133.44 million in the same period last year, representing a growth of 39.5%[40] - The total comprehensive income for the first quarter was CNY 161.38 million, compared to CNY 114.99 million in the same period last year, indicating a rise of 40.2%[41] - The total profit for the first quarter was CNY 187.69 million, compared to CNY 133.17 million in the same period last year, reflecting a growth of 40.8%[40] Assets and Liabilities - The total assets at the end of the reporting period were CNY 7,970,518,166.76, a 3.22% increase from CNY 7,721,699,746.56 at the end of the previous year[7] - The net assets attributable to shareholders increased to CNY 4,205,368,327.96, up 4.08% from CNY 4,040,506,447.75 at the end of the last year[7] - Total liabilities increased to CNY 3,452,052,980.96 from CNY 3,371,340,862.68[33] - The total assets of the company as of March 31, 2021, amounted to approximately ¥7.97 billion, an increase from ¥7.72 billion at the end of 2020[31] - The total equity attributable to shareholders reached CNY 4,040,506,447.75, while total equity was CNY 4,350,358,883.88[56] - Long-term borrowings rose significantly by 115.34% to ¥653.17 million as of March 31, 2021, compared to ¥303.33 million at the end of 2020, indicating new financing activities[18] - The company’s total liabilities increased, with short-term borrowings reported at 837,403,586.20 CNY, consistent with previous levels[55] Cash Flow - The net cash flow from operating activities was negative at CNY -248,079,595.26, a decline of 44.17% compared to CNY -172,069,444.30 in the same period last year[7] - Cash inflows from operating activities amounted to CNY 1.70 billion, an increase from CNY 1.44 billion year-on-year, representing a growth of 18.4%[47] - The net cash flow from investment activities was -91,835,373.79 CNY, contrasting with a positive 411,324,713.62 CNY in the prior year[48] - Cash inflow from financing activities totaled 893,724,888.38 CNY, compared to 572,000,000.00 CNY previously, reflecting an increase in financing efforts[49] - The ending balance of cash and cash equivalents was 920,721,238.11 CNY, down from 1,223,703,360.29 CNY year-over-year[49] Expenses - Sales expenses increased by 66.10% to ¥642.22 million in Q1 2021 from ¥386.65 million in Q1 2020, reflecting a recovery in promotional activities[18] - Total operating costs for Q1 2021 amounted to CNY 1,550,245,400.86, up from CNY 1,173,792,477.37 in the previous period[39] - Research and development expenses decreased to CNY 64,829,504.01 from CNY 96,748,171.03 year-over-year[39] - The company’s management expenses increased to CNY 12.37 million from CNY 7.05 million, representing a rise of 75.0%[43] Shareholder Information - The company reported a total of 19,794 common shareholders at the end of the reporting period[10] - The company has committed to not transferring shares for 36 months following significant asset restructuring and share issuance[14] - The company reported no significant non-operating fund occupation by controlling shareholders during the reporting period[25] Other Information - The company has not undergone an audit for the first quarter report, indicating that the figures are unaudited[60] - The company has a capital reserve of CNY 204,937,847.37, reflecting its financial stability[56] - The company’s retained earnings were reported at CNY 2,440,240,798.86, showcasing its ability to reinvest profits[56] - The company reported other income of CNY 2.82 million, up from CNY 0.86 million in the previous year, showing a significant increase of 228.5%[40]